A5103100643- Lymphoma Diagnosis and Treatment
- Platelet Disorders and Treatments
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Blood groups and transfusion
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Cancer-related molecular mechanisms research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Bioactive natural compounds
- Chemokine receptors and signaling
- Mesenchymal stem cell research
- RNA modifications and cancer
- Heparin-Induced Thrombocytopenia and Thrombosis
- Inflammatory Biomarkers in Disease Prognosis
- Blood properties and coagulation
- HER2/EGFR in Cancer Research
- Glycosylation and Glycoproteins Research
- Circular RNAs in diseases
- Hematopoietic Stem Cell Transplantation
- Virus-based gene therapy research
- Protein Degradation and Inhibitors
- Mechanisms of cancer metastasis
- Galectins and Cancer Biology
- Thermal Radiation and Cooling Technologies
Anhui Medical University
2014-2024
First Affiliated Hospital of Anhui Medical University
2014-2024
Detection Limit (United States)
2022
Abstract Background Hetrombopag, a novel thrombopoietin receptor agonist, has been found in phase I studies to increase platelet counts and reduce bleeding risks adults with immune thrombocytopenia (ITP). This III study aimed evaluate the efficacy safety of hetrombopag ITP patients. Methods Patients who had not responded or relapsed after previous treatment were treated an initial dosage once-daily 2.5 5 mg (defined as HETROM-2.5 HETROM-5 group) matching placebo randomized, double-blind,...
Myelofibrosis (MF) is associated with several constitutional symptoms. Currently, there are few therapeutic options for MF. Jaktinib, a novel, small-molecule inhibitor of JAK, currently being studied its potential to treat This phase 2 trial investigated efficacy and safety jaktinib in the treatment MF patients. The primary end point was proportion patients ≥35% reduction spleen volume (SVR35, volume) at week 24. secondary points included improvement anemia, rates symptom response, profile....
Despite the fact that Au-Ag hollow nanoparticles (HNPs) have gained much attention as ablation agents for photothermal therapy, instability of Ag element limits their applications. Herein, excess Au atoms were deposited on surface a HNP by improving reduction power l-ascorbic acid (AA) and thereby preventing reaction between HAuCl4 in alloy nanostructure. Significantly, obtained Au-Ag@Au HNPs show excellent chemical stability an oxidative environment, together with remarkable increase...
While studies have explored the feasibility of switching between various thrombopoietin receptor agonists in treating immune thrombocytopenia (ITP), data on from eltrombopag to hetrombopag remains scarce. This post-hoc analysis a phase III trial aimed assess outcomes ITP patients who switched hetrombopag. In original trial, initially randomized placebo group were eltrombopag. Those completed this 14-week eligible switch 24-week Treatment response, defined as platelet count ≥ 50 × 10
This study aimed to explore the association between percentage of reticulated platelets (RP%) and infection, analyze value combined measurement RP% with other inflammatory indicators in diagnosing infection. A total 190 patients signs symptoms suspicious infection were included group, 70 healthy subjects comparable percentages gender age control group. Peripheral white blood cell (WBC) count, neutrophils (N%), platelet C-reactive protein (CRP), procalcitonin (PCT), RP%, axillary temperature...
Multiple myeloma (MM) is a malignancy of plasma cells that leads to marrow failure and bone lesions. Numerous studies have verified the link between long non‑coding RNAs (lncRNAs) MM. The present study aimed examine role underlying mechanism differentiation antagonizing non‑protein coding RNA (DANCR) in MM cells. relative expression levels DANCR, microRNA (miR)‑135b‑5p Krüppel‑like factor 9 (KLF9) were examined using reverse transcription‑quantitative PCR. Cell viability was assessed MTT...
Abstract Sustained expression of B‐cell receptor (BCR) critically contributes to the development diffuse large lymphoma (DLBCL). However, little is known on mechanism regulating BCR expression. In present study, we explored biological significance functional intergenic repeating RNA element (FIRRE) in DLBCL and its regulation BCR. Functional impacts FIRRE cell viability, transformation, apoptosis were examined by MTT, colony formation, flow cytometry, respectively. The interaction between...
T-cell immunoglobulin and mucin domain-containing molecule 3 (TIM-3) expresses on leukemic stem progenitor populations of non-M3 acute myeloid leukemia (AML) as well T lymphocytes. TIM-3 is thought to be involved in the self-renewal cells immune escape AML cells, however its correlation with prognosis still controversial worthy further investigation.we simultaneously assessed expression levels blasts lymphocytes bone marrow de novo patients using flow cytometry. The correlations between...
To investigate the predictive value of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte (PLR) for patients with diffuse large B-cell lymphoma (DLBCL).The clinical data 57 DLBCL admitted in First Affiliated hospital Anhui Medical University were analyzed retrospectively. According to ROC curve, cut-off NLR PLR was deterimined, divided into high low NLR/PLR groups before first chamotherapy. Then relation overall survival (OS) progression-free (PFS) by univariate multivariate COX...
KIF2A has been shown to be involved in the regulation of AML pathology, however, mechanistic role not fully identified. The present study aimed identify underlying mechanism cell function and chemosensitivity. A total 58 patients with 30 healthy subjects were enrolled for clinical analysis. cells (KG‑1 Kasumi‑1) transfected or control small interfering (si)RNA. PI3K/AKT pathway activator (740 Y‑P) RhoA overexpression plasmid added rescue effect siRNA. Cell proliferation, apoptosis,...
Cutaneous T-cell lymphoma (CTCL) is associated with the downregulation of miR-337 expression, although exact underlying mechanism unknown. In present work, we investigated molecular and function in regulating CTCL cell viability invasion. We observed that expression was downregulated both tumors lines. Furthermore, CCK assay, BrdU incorporation flow cytometry revealed transfection mimic resulted decreased proliferation increased apoptotic levels cells. Results Transwell migration assay...
Bone marrow-derived mesenchymal stem cells (BM-MSCs) in the marrow stroma provide a scaffold for hematopoiesis. Chemokine stromal cell-derived factor-1 (SDF-1) and its receptor CXCR4 have been shown to affect engraftment of hematopoietic cells. However, little is known about SDF-1/CXCR4's functions regulating BM-MSCs humans. As an initial step toward this issue, we evaluated expression SDF-1/CXCR4 from cohort adolescents young adults with acute lymphoblastic leukemia (ALL). We found decrease...
Tocilizumab is a well-practiced strategy to manage cytokine release syndrome (CRS) after chimeric antigen receptor T cell (CAR-T) therapy. However, varied efficiency in CRS mitigation by tocilizumab has been reported highlight affecting variables such as tumor types and timing of the administration. The objective this study identify different curative effect between diffuse large B-cell lymphoma (DLBCL) acute lymphoblastic leukemia (ALL) early use for prophylaxis treatment CRS. By...
The hypomethylating agent decitabine is the standard therapy for intermediate or high risk myelodysplastic syndrome (MDS).In this trial, 191 adult patients with intermediate/high MDS (IPSS score ≥ 0.5) randomly received using a regimen (20 mg/m2 /day 5 consecutive days; n = 94) an extended lower daily dose (12 8 97) every 4 weeks, total of cycles.The median follow-up was 14 months (range 2-36). primary end point overall response rate in intent-to-treat analysis 41.5% and 38.1% dosing arms,...